HAL Allergy Benelux B.V.: Nieuws

HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy.

The positive results of this pivotal study will support HAL Allergy to obtain full marketing authorization of this product from the Paul Ehrlich...

Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath

Leiden, the Netherlands – In a recent open label clinical study Lozano and co-workers investigated the effect of subcutaneous specific immunotherapy...

Positive outcome of the phase II dose range finding study with SUBLIVAC® FIX Birch

Leiden, the Netherlands – HAL Allergy B.V. today announced a positive outcome of the dose range finding study with its sublingual immunotherapy...

HAL Allergy completes patient enrollment for its Phase II trial with SUBLIVAC® FIX Phleum pratense

LEIDEN - the Netherlands – HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC®...

HAL Allergy completes patient enrollment for its Phase II trial with SUBLIVAC® FIX Birch

LEIDEN - the Netherlands – HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC®...

HAL Allergy introduces Scientific Advisory Board

LEIDEN - the Netherlands – HAL Allergy B.V. today introduces their Scientific Advisory Board. This group of specialists will advise and assist the...

HAL Allergy completes patient enrollment for its Phase II trial with PURETHAL® Mites

LEIDEN - the Netherlands – HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding...

HAL Allergy includes first patient in phase II PURETHAL® Mites study

LEIDEN - the Netherlands (31-10-2011) – HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding...